Quarterly report pursuant to sections 13 or 15(d)

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v2.4.0.8
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2013
Disclosure Text Block [Abstract]  
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]
   

Carrying Values

   

Estimated

Fair Value

 

Related party Boston Scientific convertible notes payable

  $ 4,338,601     $ 3,906,979  

Note payable

    3,818,342       3,818,342  

Junior secured notes payable

    217,560       2,062,546  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
   

Quoted Prices in

Active Markets

(Level 1)

   

Significant

Observable

Inputs (Level 2)

   

Significant

Unobservable

Inputs (Level 3)

   

Total Fair

Value

 
                                 

Derivative liability - warrants

  $ -     $ -     $ 4,106,224     $ 4,106,224  

Derivative liability - conversion option

    -       -       -       -  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

As of September 30,

 
   

2013

   

2012

 

Stock options

    6,739,877       6,132,127  

Warrants

    12,203,489       8,945,247  

Shares under convertible note agreements

    542,325       4,371,029  
      19,485,691       19,448,403